Grey Wolf Therapeutics
Clinical trials sponsored by Grey Wolf Therapeutics, explained in plain language.
-
New pill aims to halt debilitating spine disease
Disease control Recruiting nowThis study is testing a new oral pill, GRWD0715, to see if it is safe and can help control axial spondyloarthritis (axSpA), a long-term inflammatory disease that mainly affects the spine and pelvis. The pill works by targeting a specific enzyme thought to trigger the harmful immu…
Phase: PHASE1, PHASE2 • Sponsor: Grey Wolf Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug aims to wake up the immune system to fight advanced cancers
Disease control Recruiting nowThis early-stage study is testing a new oral drug called GRWD5769, which is designed to help the body's immune system recognize and attack cancer cells. It will be given alone and in combination with an existing immunotherapy drug (cemiplimab/Libtayo®) to adults with advanced sol…
Phase: PHASE1, PHASE2 • Sponsor: Grey Wolf Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC